Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Operating Leases (2019 - 2025)

China Pharma Holdings (CPHI) has disclosed Operating Leases for 7 consecutive years, with $128257.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases changed N/A year-over-year to $128257.0, compared with a TTM value of $128257.0 through Sep 2025, changed N/A, and an annual FY2024 reading of $39323.0, down 1.47% over the prior year.
  • Operating Leases was $128257.0 for Q3 2025 at China Pharma Holdings, up from $39323.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $169893.0 in Q2 2021 and bottomed at $20008.0 in Q1 2024.
  • Average Operating Leases over 5 years is $64651.9, with a median of $44181.0 recorded in 2021.
  • The sharpest move saw Operating Leases plummeted 76.9% in 2021, then soared 83.71% in 2023.
  • Year by year, Operating Leases stood at $44181.0 in 2021, then dropped by 8.46% to $40445.0 in 2022, then dropped by 1.32% to $39910.0 in 2023, then dropped by 1.47% to $39323.0 in 2024, then skyrocketed by 226.16% to $128257.0 in 2025.
  • Business Quant data shows Operating Leases for CPHI at $128257.0 in Q3 2025, $39323.0 in Q4 2024, and $20008.0 in Q1 2024.